22 May 2023

Permira Appoints David Floyd as Senior Adviser

“David has been a true partner and friend to us and I’m thrilled to welcome him more formally to the Permira team. His wealth of experience in the Medtech space in senior managerial roles and his expertise in building leading global businesses will be very valuable to the team as we continue to successfully invest in the attractive healthcare space”.
Silvia Oteri
Partner and Head of Healthcare
Share to Linkedin

London, 23 May 2023 – Permira, the global private equity firm, today announced the appointment of David Floyd as a Senior Adviser to its global Healthcare team.

David brings over 35 years of experience in healthcare and is widely regarded as one of the medical device industry’s leading executives due to the breadth of his senior leadership experience, including areas such as orthopaedics, surgical tools, neurotechnology and spine products. David’s professional experience spans international leadership roles including Group President of Orthopaedics, Stryker Corporation from 2012 to 2019, where he oversaw a number of acquisitions – most notably Mako Surgical, and also Instratek, Small Bone Innovations and Stanmore Implants.

He was previously Worldwide President, DePuy Orthopaedics (today DePuy Synthes, a business of Johnson & Johnson) initially with US responsibility, before being promoted to global responsibility, and also worked at Abbott Laboratories, where his roles included President of spine products.

David currently serves as Chairman of Corin Group, a tech-enabled orthopaedic implant company in which the Permira funds invested in 2018. He also served as interim CEO at Corin in 2021. He also serves as a board member of Merit Medical Systems, a medical device company specializing in interventional products in the cardiology, radiology, oncology and vascular surgery markets, and Healthcare Outcomes Performance Company, a fast growing provider of musculoskeletal value-based care treatment in the US, delivered primarily in physician practices, ASCs and hospitals. David holds a Bachelor of Science from Grace College & Seminary in the US.

Permira is an active investor in the Healthcare sector, having deployed over €4 billion to partner with ~20 companies globally. Current investments from the Permira funds in the sector include: Kedrion and BPL, Neuraxpharm, Cambrex, Quotient Sciences, I-Med and Corin. 

David Floyd added: “Ever since I started working closely with Permira through my position at Corin, I have always been impressed by their deep sector understanding and partnership philosophy. I look forward to working with the broader Healthcare team to help drive long-term value for the Permira funds, their portfolio companies and stakeholders.”

Permira’s Senior Advisers partner with investment teams to identify new opportunities and help management teams drive value through scaling champions globally. David’s appointment follows the Healthcare team’s recent appointment of healthtech veteran Andy Eckert in 2022.